Cancer Research UK Adopts Dharmacon Gene-Silencing Technology
Dharmacon, a supplier of innovative RNA and RNA-interference (RNAi) research products, has announced an agreement to provide siRNA libraries to Cancer Research UK, a charity dedicated to research on the causes, treatment and prevention of cancer. According to the announcement, the siRNA libraries, which were developed using Dharmacon's proprietary SMARTselection and SMARTpool technology platforms, initially include protein kinase genes and associated pathways. Cancer Research UK is the world's largest volunteer-based cancer research organisation, supporting the work of more than 3,000 research scientists, doctors and nurses at 80 leading academic institutions across the United Kingdom. It is one of the few independent organisations with the ability to take pioneering cancer research from the laboratory bench to the patient's bedside, supporting both basic research and clinical trials.